Lixisenatide U.S. label context · version 1
This page preserves this version's wording and source pins. Open the current profile →
What does the U.S. product label say?
ADLYXIN, revised November 2024 · Read September 15, 2026 · Preserved label summary 1
Which population and use does the label cover?
This single-ingredient label covers glycemic control alongside diet and exercise in adults with type 2 diabetes. It is separate from the insulin glargine/lixisenatide combination label cited by the profile, and does not establish current commercial availability. Label: 1 ↗
Which safety limits matter?
The label contraindicates severe hypersensitivity and addresses anaphylaxis, pancreatitis, hypoglycemia with insulin or insulin secretagogues, acute kidney injury, immunogenicity, gallbladder disease and aspiration during anesthesia or deep sedation. It does not recommend use in gastroparesis. Label: 4, 5, 6 ↗
Label edition and source pins
FDA-hosted U.S. prescribing information. This account concerns this product and label edition; other formulations and jurisdictions require their own records.
ADLYXIN, revised November 2024: U.S. prescribing information
Label PDF SHA-256: 62efbf5418ef53b5e665d679c1184fa7bc006960fb487a68aa04bf1e2a04d597.